

HTA and IDEAL

(a “NICE perspective”)

Bruce Campbell

Non-Executive Director Medicines and Healthcare products
Regulatory Agency (MHRA)

Past Chair NICE Interventional Procedures and Medical
Technologies Advisory Committees

IDEAL Conference

5 May 2017

Declaration

I have sweated blood
for Peter McCulloch
and application of IDEAL!

IDEAL is so clearly sensible BUT

NICE:

- Has to evaluate procedures/devices on the evidence available at the time
- Is process-driven: no option for delay
- Has limited (some) influence on future evidence generation (“What do you want?!”)

NICE IP Research Recommendations

- Specify OUTCOMES but seldom DESIGN
- May specify “could/should include data collection”
- Often specifies particular registry and occasionally specific trial

Could IDEAL could inform recommendations?

Many conversations about IDEAL

- Look at IDEAL Stages of a series of new procedures seen by NICE IPAC
- What recommendations were made?
- What research was recommended?

How, therefore, might IDEAL be applied?

NICE Research capacity through its External Assessment Centres (EACs)

- Specific research is an option for MTAC recommendation (review in 2 years)
- EAC oversees collaboration, design, ethics

Could IDEAL assist this process (and subsequent, continuing evidence generation)?

Transition of device from one type of NICE guidance to another

From New Interventional Procedure evaluation

EVIDENCE: Safety/efficacy

Specifies *circumstances for its use*

To Medical Technology evaluation

EVIDENCE: Clinical and cost consequences/advantages

Encourages *“Evidence supports adoption ...”*

To Technology Appraisal

EVIDENCE: Clinical and cost effectiveness

Mandates *“Should be offered to these patients ...”*

How could IDEAL align with these transitions?

IDEAL-D

Stage 0: Important, but not traditionally part of IP/MT considerations – focus *clinical*

Stage 1: First in man never an issue for NICE

Stage 2-3 ‘merged’: Helpful simplification

Stage 4: Good data collection much earlier
Very helpful – fundamental to many decisions on new procedures

Evidence generation

IDEAL describes the framework for an overall strategy to:

- **Plan ahead for** regulators, HTA, payers, clinicians, patients
- **Maximise relevance** and value of evidence for these successive audiences

